Multivariate analyses
| . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Grade 2-4 acute GVHD | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.62 (0.87-3.04) | .13 |
| Donor type | ||
| HLA-matched sibling | 1.00 | — |
| Unrelated donor | 2.45 (1.24-4.90) | .01 |
| Chronic GVHD | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 0.89 (0.49-1.61) | .71 |
| T-cell depletion | ||
| Yes | 1.00 | — |
| None | 1.91 (1.11-3.26) | .02 |
| Donor type | ||
| HLA-matched sibling | 1.00 | — |
| Unrelated donor | 2.30 (1.14-4.65) | .02 |
| Transplant-related mortality | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.53 (0.54-4.35) | .42 |
| T-cell depletion | ||
| None | 1.00 | — |
| Yes | 2.84 (1.26-6.37) | .02 |
| Relapse | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.26 (0.69-2.31) | .45 |
| Performance score | ||
| 90-100 | 1.00 | — |
| <90 | 3.00 (1.75-5.13) | <.0001 |
| Treatment failure | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.29 (0.77-2.16) | .33 |
| Performance score | ||
| 90-100 | 1.00 | — |
| <90 | 2.98 (1.86-4.70) | <.0001 |
| Overall survival | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.24 (0.74-2.08) | .41 |
| Performance score | ||
| 90-100 | 1.00 | — |
| <90 | 3.22 (2.01-5.16) | <.0001 |
| Prior significant fungal infection | ||
| None | 1.00 | — |
| Yes | 1.83 (1.12-2.98) | .02 |
| . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Grade 2-4 acute GVHD | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.62 (0.87-3.04) | .13 |
| Donor type | ||
| HLA-matched sibling | 1.00 | — |
| Unrelated donor | 2.45 (1.24-4.90) | .01 |
| Chronic GVHD | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 0.89 (0.49-1.61) | .71 |
| T-cell depletion | ||
| Yes | 1.00 | — |
| None | 1.91 (1.11-3.26) | .02 |
| Donor type | ||
| HLA-matched sibling | 1.00 | — |
| Unrelated donor | 2.30 (1.14-4.65) | .02 |
| Transplant-related mortality | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.53 (0.54-4.35) | .42 |
| T-cell depletion | ||
| None | 1.00 | — |
| Yes | 2.84 (1.26-6.37) | .02 |
| Relapse | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.26 (0.69-2.31) | .45 |
| Performance score | ||
| 90-100 | 1.00 | — |
| <90 | 3.00 (1.75-5.13) | <.0001 |
| Treatment failure | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.29 (0.77-2.16) | .33 |
| Performance score | ||
| 90-100 | 1.00 | — |
| <90 | 2.98 (1.86-4.70) | <.0001 |
| Overall survival | ||
| Reduced-intensity regimen | 1.00 | — |
| Myeloablative regimen | 1.24 (0.74-2.08) | .41 |
| Performance score | ||
| 90-100 | 1.00 | — |
| <90 | 3.22 (2.01-5.16) | <.0001 |
| Prior significant fungal infection | ||
| None | 1.00 | — |
| Yes | 1.83 (1.12-2.98) | .02 |